Technical Analysis for VTVT - vTv Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 1.74 1.16% 0.02
VTVT closed up 1.16 percent on Friday, March 22, 2019, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical VTVT trend table...

Date Alert Name Type % Chg
Mar 22 Narrow Range Bar Range Contraction 0.00%
Mar 22 NR7 Range Contraction 0.00%
Mar 22 Lower Bollinger Band Walk Weakness 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Lower Bollinger Band Walk Weakness 1.16%
Mar 21 Wide Bands Range Expansion 1.16%
Mar 21 Below Lower BB Weakness 1.16%

Older signals for VTVT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.
Medicine Chemistry Biopharmaceutical Diseases Diabetes Autoimmune Diseases Inflammation Alzheimer's Disease Organic Chemistry Psoriasis Parkinson's Disease Inflammatory Diseases Chronic Obstructive Pulmonary Disease Pyridines Treatment Of Alzheimer's Disease Tyrosine Kinase Inhibitors Biotie Therapies Treatment Of Chronic Obstructive Pulmonary Disease Buparlisib Treatment Of Inflammation
Is VTVT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.09
52 Week Low 0.65
Average Volume 900,106
200-Day Moving Average 1.9471
50-Day Moving Average 2.4628
20-Day Moving Average 2.1555
10-Day Moving Average 2.033
Average True Range 0.196
ADX 15.69
+DI 17.1325
-DI 24.3996
Chandelier Exit (Long, 3 ATRs ) 2.032
Chandelier Exit (Short, 3 ATRs ) 2.298
Upper Bollinger Band 2.5691
Lower Bollinger Band 1.7419
Percent B (%b) 0.0
BandWidth 38.376247
MACD Line -0.1632
MACD Signal Line -0.1203
MACD Histogram -0.0429
Fundamentals Value
Market Cap 16.87 Million
Num Shares 9.69 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -1.04
Price-to-Sales 535.97
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.85
Resistance 3 (R3) 1.85 1.81 1.83
Resistance 2 (R2) 1.81 1.79 1.81 1.82
Resistance 1 (R1) 1.78 1.77 1.76 1.78 1.82
Pivot Point 1.74 1.74 1.74 1.74 1.74
Support 1 (S1) 1.71 1.72 1.69 1.71 1.66
Support 2 (S2) 1.67 1.70 1.67 1.66
Support 3 (S3) 1.64 1.67 1.65
Support 4 (S4) 1.64